174060-40-3

Basic information

• Product Name: Pyridine, 3-(2R)-oxiranyl- (9CI)
• Synonyms: Pyridine, 3-(2R)-oxiranyl- (9CI)
• CAS NO: 174060-40-3
• Molecular Formula: C₇H₇NO
• Molecular Weight: 121.13658
• Product Categories: PYRIDINE
• Mol File: 174060-40-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyridine, 3-(2R)-oxiranyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-(2R)-oxiranyl- (9CI)(174060-40-3)
• EPA Substance Registry System: Pyridine, 3-(2R)-oxiranyl- (9CI)(174060-40-3)

Safety Data

• Hazardous Substances Data: 174060-40-3(Hazardous Substances Data)

Upstream product

• 173901-03-6 (R)-2-chloro-1-(3-pyridyl)-ethanol 
• 500-22-1 3-pyridinecarboxaldehyde 
• 111324-03-9 1-tert-butyl-2,2,4,4,4-pentakis(dimethylamino)-2Λ⁵,4Λ⁵-catenadi(phosphazene) 
• 17694-68-7 3-(2-bromoacetyl)pyridine hydrobromide 
• 112022-83-0 (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole 
• 6221-12-1 3-Bromoacetylpyridine 
• 391906-07-3 (1R)-2-bromo-1-(3-pyridinyl)-1-ethanol 

Downstream Products

• 391906-13-1 (1R)-2-amino-1-(3-pyridinyl)-1-ethanol 
• 173901-04-7 (1 R)-2-[(4-aminophenethyl)amino]-1-(3-pyridinyl)-1-ethanol 
• 228709-67-9 2-[(2R)-(2-hydroxy-2-pyridin-3-ylethylamino)methyl]chroman-6-sulfonic acid {4-[4-(3-cyclopentylpropyl)-5-oxo-4,5-dihydrotetrazol-1-yl]phenyl}amide 
• 173901-05-8 (R)-N-[2-(4-aminophenyl)ethyl]-2-hydroxy-2-(3-pyridyl)ethylcarbamic acid 1,1-dimethylethyl ester 

Relevant articles and documents

Highly enantioselective ylide-mediated synthesis of terminal epoxides

The highly efficient asymmetric epoxidation of aldehydes by methylene transfer is now possible using new sulfonium salts. This journal is

NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS

This invention relates to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE

The compound of the formula (I): wherein W is a group of the following formula (VIII) binding to any possible position on the Q: Q is, together with W, a group of the formula: -C(M=C(R3A)-N(R3)-, etc.; R3A is H or optionally substituted lower alkyl; R4, R5, R6, and R7 are independently H or optionally substituted lower alkyl; R1 is optionally substituted lower alkyl, etc.; R2 is H, etc.; R3 is H, etc.; Ar is phenyl, etc., or a pharmaceutically acceptable salt thereof, where these compounds exhibiting β3-adrenoceptor-stimulating activity and being useful as a medicament for treatment of obesity, etc.

Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists

This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS

This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

Azolidines as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein, A, X, Y, Z, W, R1, R2, R3, R4, R5, and R6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

2,4-Thiazolidinediones as potent and selective human β3 agonists

Methylsulfonamide substituted 2,4-thiazolidinedione 22c is a potent (EC50 = 0.01 μM, IA = 1.19) and selective (more than 110-fold over β1 and β2 agonist activity) β3 agonist. This compound has also been proven to be active and selective in an in vivo mode.

SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS

This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA-3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Substituted sulfonamides are selective β 3 adrenergic receptor agonists with very little β 1 and β 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent

SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Substituted sulfonamides are selective β 3 adrenergic receptor agonists with very little β 1 and β 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent